Light chain deposition disease in an older adult patient successfully treated with long-term administration of bortezomib, melphalan and prednisone

Hiroto Hiyamuta; Shunsuke Yamada; Yuta Matsukuma; Akihiro Tsuchimoto; Toshiaki Nakano; Masatomo Taniguchi; Kosuke Masutani; Goichi Yoshimoto; Tsuyoshi Muta; Koichi Akashi; Takanari Kitazono; Kazuhiko Tsuruya

doi:10.2169/internalmedicine.55.5752

Light chain deposition disease in an older adult patient successfully treated with long-term administration of bortezomib, melphalan and prednisone

Hiroto Hiyamuta, Shunsuke Yamada, Yuta Matsukuma, Akihiro Tsuchimoto, Toshiaki Nakano, Masatomo Taniguchi, Kosuke Masutani, Goichi Yoshimoto, Tsuyoshi Muta, Koichi Akashi, Takanari Kitazono, Kazuhiko Tsuruya

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

A 70-year-old woman was admitted to our hospital because of fatigue and renal dysfunction and was diagnosed with light chain deposition disease (LCDD) with multiple organ involvement (kidney, thyroid gland, heart and eyes). After chemotherapy with bortezomib, cyclophosphamide and dexamethasone, hepatobiliary enzyme levels increased abruptly. A liver biopsy showed light chain deposition in Disse spaces. After two years of treatment with bortezomib, melphalan and prednisone (VMP) administered at shorter intervals relative to regular cycles, the patient showed a hematological and organ response. This case indicates that a relatively low dose intensity VMP regimen is preferable for elderly patients with LCDD with multiple organ involvement.

Original language	English (US)
Pages (from-to)	1319-1325
Number of pages	7
Journal	Internal Medicine
Volume	55
Issue number	10
DOIs	https://doi.org/10.2169/internalmedicine.55.5752
State	Published - 2016

Keywords

Cardiac involvement
Liver involvement
Multiple myeloma
Ocular involvement
VMP therapy

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.2169/internalmedicine.55.5752

Cite this

Hiyamuta, H., Yamada, S., Matsukuma, Y., Tsuchimoto, A., Nakano, T., Taniguchi, M., Masutani, K., Yoshimoto, G., Muta, T., Akashi, K., Kitazono, T., & Tsuruya, K. (2016). Light chain deposition disease in an older adult patient successfully treated with long-term administration of bortezomib, melphalan and prednisone. Internal Medicine, 55(10), 1319-1325. https://doi.org/10.2169/internalmedicine.55.5752

Hiyamuta, H, Yamada, S, Matsukuma, Y, Tsuchimoto, A, Nakano, T, Taniguchi, M, Masutani, K, Yoshimoto, G, Muta, T, Akashi, K, Kitazono, T & Tsuruya, K 2016, 'Light chain deposition disease in an older adult patient successfully treated with long-term administration of bortezomib, melphalan and prednisone', Internal Medicine, vol. 55, no. 10, pp. 1319-1325. https://doi.org/10.2169/internalmedicine.55.5752

@article{f0f6760789624bcb9fcee2ff6508d4db,

title = "Light chain deposition disease in an older adult patient successfully treated with long-term administration of bortezomib, melphalan and prednisone",

abstract = "A 70-year-old woman was admitted to our hospital because of fatigue and renal dysfunction and was diagnosed with light chain deposition disease (LCDD) with multiple organ involvement (kidney, thyroid gland, heart and eyes). After chemotherapy with bortezomib, cyclophosphamide and dexamethasone, hepatobiliary enzyme levels increased abruptly. A liver biopsy showed light chain deposition in Disse spaces. After two years of treatment with bortezomib, melphalan and prednisone (VMP) administered at shorter intervals relative to regular cycles, the patient showed a hematological and organ response. This case indicates that a relatively low dose intensity VMP regimen is preferable for elderly patients with LCDD with multiple organ involvement.",

keywords = "Cardiac involvement, Liver involvement, Multiple myeloma, Ocular involvement, VMP therapy",

author = "Hiroto Hiyamuta and Shunsuke Yamada and Yuta Matsukuma and Akihiro Tsuchimoto and Toshiaki Nakano and Masatomo Taniguchi and Kosuke Masutani and Goichi Yoshimoto and Tsuyoshi Muta and Koichi Akashi and Takanari Kitazono and Kazuhiko Tsuruya",

note = "Publisher Copyright: {\textcopyright} 2016 The Japanese Society of Internal Medicine.",

year = "2016",

doi = "10.2169/internalmedicine.55.5752",

language = "English (US)",

volume = "55",

pages = "1319--1325",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "10",

}

TY - JOUR

T1 - Light chain deposition disease in an older adult patient successfully treated with long-term administration of bortezomib, melphalan and prednisone

AU - Hiyamuta, Hiroto

AU - Yamada, Shunsuke

AU - Matsukuma, Yuta

AU - Tsuchimoto, Akihiro

AU - Nakano, Toshiaki

AU - Taniguchi, Masatomo

AU - Masutani, Kosuke

AU - Yoshimoto, Goichi

AU - Muta, Tsuyoshi

AU - Akashi, Koichi

AU - Kitazono, Takanari

AU - Tsuruya, Kazuhiko

PY - 2016

Y1 - 2016

N2 - A 70-year-old woman was admitted to our hospital because of fatigue and renal dysfunction and was diagnosed with light chain deposition disease (LCDD) with multiple organ involvement (kidney, thyroid gland, heart and eyes). After chemotherapy with bortezomib, cyclophosphamide and dexamethasone, hepatobiliary enzyme levels increased abruptly. A liver biopsy showed light chain deposition in Disse spaces. After two years of treatment with bortezomib, melphalan and prednisone (VMP) administered at shorter intervals relative to regular cycles, the patient showed a hematological and organ response. This case indicates that a relatively low dose intensity VMP regimen is preferable for elderly patients with LCDD with multiple organ involvement.

AB - A 70-year-old woman was admitted to our hospital because of fatigue and renal dysfunction and was diagnosed with light chain deposition disease (LCDD) with multiple organ involvement (kidney, thyroid gland, heart and eyes). After chemotherapy with bortezomib, cyclophosphamide and dexamethasone, hepatobiliary enzyme levels increased abruptly. A liver biopsy showed light chain deposition in Disse spaces. After two years of treatment with bortezomib, melphalan and prednisone (VMP) administered at shorter intervals relative to regular cycles, the patient showed a hematological and organ response. This case indicates that a relatively low dose intensity VMP regimen is preferable for elderly patients with LCDD with multiple organ involvement.

KW - Cardiac involvement

KW - Liver involvement

KW - Multiple myeloma

KW - Ocular involvement

KW - VMP therapy

UR - http://www.scopus.com/inward/record.url?scp=84968854162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84968854162&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.55.5752

DO - 10.2169/internalmedicine.55.5752

M3 - Article

C2 - 27181540

AN - SCOPUS:84968854162

SN - 0918-2918

VL - 55

SP - 1319

EP - 1325

JO - Internal Medicine

JF - Internal Medicine

IS - 10

ER -

Light chain deposition disease in an older adult patient successfully treated with long-term administration of bortezomib, melphalan and prednisone

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this